Saturday 17 October 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024. In the quarter to June 2026, revenue grew 25.7%, EPS grew 19.5% and free cash flow fell 4.95%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
117.81
17.65
−13.03%
Follow GRAL
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 6 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 4.53 | 21.37 |
Altman Z-Score |
— | — | (5.97) | 0.37 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 5.21 | (8.53) | (2.86) |
P/Operating CF |
(2.05) | (2.05) | (6.09) | (49.32) |
P/B ratio |
0.12 | 0.12 | 0.23 | 1.22 |
Price to Tangible BV |
0.12 | 0.12 | 1.17 | 4.33 |
EV/Sales |
0.00 | 0.00 | (1.54) | 15.23 |
EV/EBITDA |
0.00 | 0.00 | 0.32 | 0.00 |
EV/Operating CF |
(0.41) | (0.41) | 0.34 | (7.50) |
EV/FCF |
(0.40) | (0.40) | 0.33 | (7.47) |
Quick Ratio |
— | 0.70 | 10.19 | 11.58 |
Current Ratio |
— | 0.95 | 10.66 | 11.97 |
Net Debt/EBITDA |
0.00 | 0.15 | 1.24 | 2.27 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.05 | 0.04 | 0.05 |
Operating CF/Net income |
0.10 | 0.41 | 0.28 | 0.73 |
Capex/Depreciation |
0.00 | (0.01) | 0.00 | (0.01) |
| 0.00% | 0.00% | (65.92%) | (16.07%) | |
| 0.00% | (74.90%) | (58.78%) | (13.83%) | |
ROIC |
0.00% | (26.69%) | (78.64%) | (21.00%) |
Return on Tangible Assets |
0.00% | (1,892.43%) | (249.63%) | (44.10%) |
Average Days of Receivables |
0.00 | 66.42 | 59.03 | 45.37 |
Research and Development Expense of Revenue |
593.30% | 363.83% | 256.68% | 133.04% |
Selling, General and Administrative Expense of Revenue |
533.64% | 389.41% | 292.86% | 187.40% |
Intangible Assets out of Total Assets |
0.00 | 0.91 | 0.68 | 0.63 |
Share Based Compensation of Revenue |
62.50% | 21.83% | 25.70% | 39.60% |
Graham Net Nets |
(0.26) | (0.26) | 0.60 | 0.19 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(621.92%) | (621.92%) | (363.81%) | (13.06%) |
Free Cash Flow Yield |
(192.99%) | (192.99%) | (102.27%) | (9.53%) |
Revenue per Share |
1.79 | 3.00 | 3.94 | 4.00 |
Operating CF per Share |
(18.08) | (19.19) | (18.09) | (8.14) |
Capex per Share |
(0.74) | (0.42) | (0.16) | (0.02) |
Free Cash Flow per Share |
(18.81) | (19.60) | (18.26) | (8.16) |
Cash per Share |
0.00 | 3.13 | 23.93 | 24.61 |
Shareholders Equity per Share |
0.00 | 117.43 | 78.47 | 70.14 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 117.43 | 78.47 | 70.14 |
Free Cash Flow |
(584.17) | (608.69) | (582.36) | (299.92) |
Working Capital |
— | (7.54) | 742.94 | 874.18 |
Capital Expenditures |
(22.86) | (12.89) | (5.21) | (0.91) |
Net Current Asset Value |
0.00 | (111.56) | 339.96 | 609.70 |
EV/EBIT |
0.00 | 0.00 | 0.09 | 0.00 |
Capex to Sales |
0.41 | 0.14 | 0.04 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.00 | 10.32 | 22.82 | 3.15 |
Cash ROIC |
0.00% | (16.26%) | (17.83%) | (8.61%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 6.74 | 7.62 |
Accounts Payable Turnover |
0.00 | 0.00 | 16.61 | 60.56 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 38.05 | 8.68 | 3.62 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 18.63 | 19.30 |
Average Payables |
— | — | 12.26 | 3.46 |
Average Assets |
— | 1,956.91 | 3,448.56 | 2,952.66 |
Average Common Equity |
— | — | 3,074.80 | 2,540.63 |
Columns are period end dates